BTIG analyst Robert Hazlett raised his price target for Eiger BioPharmaceuticals to $47 from $44 after the company announced that FDA granted Lonafarnib Breakthrough Therapy for the treatment of Progeria and progeroid laminopathies. The analyst argues that Breakthrough status adds material regulatory and clinical validation to Lonafarnib's accelerated efforts in Progeria and should enable more rapid FDA review. An NDA filing istargeted for early 2019, he notes. Hazlett now models U.S. approval in Progeria in 2019, a Priority Review Voucher awarded and monetized around yearend 2019, and use in progeriod laminopathies, which modestly lifts NPV estimates. The analyst reiterates a Buy rating on the shares.